Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma

Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). Most BCC patients experience significant clinical benefit on vismodegib, however, some develop re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Sharpe, Hayley J., Pau, Gregoire, Dijkgraaf, Gerrit J., Basset-Seguin, Nicole, Modrusan, Zora, Januario, Thomas, Tsui, Vickie, Durham, Alison B., Dlugosz, Andrzej A., Haverty, Peter M., Bourgon, Richard, Tang, Jean Y., Sarin, Kavita Y., Dirix, Luc, Fisher, David C., Rudin, Charles M., Sofen, Howard, Migden, Michael R., Yauch, Robert L., de Sauvage, Frederic J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675004/
https://ncbi.nlm.nih.gov/pubmed/25759019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.02.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados